ArticleCureus2022

The "One-to-Many" Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma.

Andrea Messori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.